

1615

Docket No. SC35U-US
Customer No. 60723

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): MENON, Gopinathan Confirmation No. 1007
Serial No.: 09/521,442 Group Art Unit: 1615
Filed: March 7, 2000 Examiner: VENKAT, Jyothsna A.

For: METHOD OF TREATING SKIN CONDITIONS

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is:

1. Transmittal Letter (1 page + duplicate);
2. Information Disclosure Statement (2 pages);
3. Information Disclosure Statement by Applicant Form PTO/SB/08A and 08B (3 pages and copy of references) and
4. Return postcard.

Please charge any additional fees or credits any such fees, if necessary to Deposit Account No. 50-3782 in the name of Avon Products, Inc. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: June 7, 2007

Charles J. Zelle, Esq.
Reg. No. 28,682
AVON PRODUCTS, INC.
Avon Place
Suffern, New York 10901
Tel: 845-369-2113
Fax: 845-369-2900

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Kathy S. Abrams
SIGNATURE

6-7-07
DATE



Docket No. SC35U-US
Customer No. 60723

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): MENON, Gopinathan Confirmation No. 1007
Serial No.: 09/521,442 Group Art Unit: 1615
Filed: March 7, 2000 Examiner: VENKAT, Jyothsna A.
For: METHOD OF TREATING SKIN CONDITIONS

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is:

1. Transmittal Letter (1 page + duplicate);
2. Information Disclosure Statement (2 pages);
3. Information Disclosure Statement by Applicant Form PTO/SB/08A and 08B (3 pages and copy of references) and
4. Return postcard.

Please charge any additional fees or credits any such fees, if necessary to Deposit Account No. 50-3782 in the name of Avon Products, Inc. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date:

June 7, 2007

Charles J. Zeller, Esq.
Reg. No. 28,682
AVON PRODUCTS, INC.
Avon Place
Suffern, New York 10901
Tel: 845-369-2113
Fax: 845-369-2900

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Kathy S. Abrams
SIGNATURE

6-7-07
DATE



Docket No. SC35U-US
Customer No. 60723

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): MENON, Gopinathan Confirmation No. 1007
Serial No.: 09/521,442 Group Art Unit: 1615
Filed: March 7, 2000 Examiner: VENKAT, Jyothsna A.
For: METHOD OF TREATING SKIN CONDITIONS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313 1450

Dear Sir:

In accordance with applicants' duty of disclosure under 37 C.F.R. §1.56, we are enclosing Form SB/08A and SB/08B listing information that may be material to the patentability of this application.

It should be understood that attention has been called to the references that have been deemed to be pertinent to the claimed present invention. In concluding what was pertinent, the criteria employed was considered most appropriate in light of the invention shown in the present application. However, the Examiner or others may deem some other criteria to be just as appropriate or more appropriate. Therefore, the Examiner is respectfully urged to review the listed references and to make the usual careful independent search for other prior art that may be pertinent.

CERTIFICATE UNDER 37 C.F.R. §1.97 (e) FOR FILING I.D.S.

The undersigned attorney hereby certifies: that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application no more than three (3) months prior to the filing of this statement.


Applicants respectfully request favorable consideration and this application be passed to allowance.

Please charge any additional fees or credits any such fees, if necessary to Deposit Account No. 50-3782 in the name of Avon Products, Inc.

Respectfully submitted,

Date:

June 7, 2007



Charles J. Zeller, Esq.

Reg. No. 28, 682


AVON PRODUCTS, INC.

Avon Place

Suffern, New York 10901

Tel: 845-369-2113

Fax: 845-369-2900



Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	09/521,442
Filing Date	March 7, 2000
First Named Inventor	MENON, Gopinathan K.
Art Unit	1615
Examiner Name	VENKAT, Jyothsna A.
Attorney Docket Number	SC35U-US

U. S. PATENT DOCUMENTS

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/521,442
		Filing Date	March 7, 2000
		First Named Inventor	MENON, Gopinathan K.
		Art Unit	1615
		Examiner Name	VENKAT, Jyothsna A.
Sheet 2	of 3	Attorney Docket Number	SC85U-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DRAELOS, D. & MARENUS, K.; Cellulite Biology and Purported Treatment; Dermatologic Surgery; Dec. 1997, p. 1177-1181, Vol. 23, Number 12.	
		ROSEN E. & SPIEGELMAN, B.; Adipocytes as regulators of energy balance and glucose homeostasis; Nature Publishing Group; 2006; p. 847-853.	
		LARSEN, T. et al; PPARgamma agonists in the treatment of type II diabetes; ; Intl. Journal of Obesity; Feb. 2003; p. 147-161, Vol. 27, No. 2.	
		MONTAGUE, C. et al; Depot-Related Gene Expression in Human Subcutaneous and Omental Adipocytes; Diabetes; Sept. 1998; p.1384-1391, Vol. 47.	
		AVRAM, A. et al.; Subcutaneous fate in normal and diseased states; J. Am. Aca. Dermatol.; Oct. 2005; p. 671-683; Vol. 53, No. 4.	
		Muller, Y. et al.; A Functional Variant in the Peroxisome Proliferator; Diabetes, July 2003; p. 1864-1871, Vol. 52.	
		HEXSEL, D. et al.; Botanical Extracts Used in the Treatment of Cellulite; Dermatol Surg.; July 2005; p 866-872, Vol. 31:7 Part 2.	
		SEMPLE, R. et al.; PPARγ and human metabolic disease; J. of Clinical Investigation; March 2006, p. 581-589, Vol. 116, No. 3.	
		AVRAM, M; Cellulite: a review of its physiology and treatment; J. Cosmet. Laser Ther.; 2004; p. 181-185, Vol. 6	
		GIUSTI, V. et al.; Expression of Peroxisome Proliferator; Diabetes; July 2003; p. 1673-1676, Vol. 52, No. 7.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/521,442
Filing Date	March 7, 2000
First Named Inventor	MENON, Gopinathan K.
Art Unit	1615
Examiner Name	VENKAT, Jyothsna A.
Attorney Docket Number	SC85U-US

Sheet 3

of

3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MORI, Y., et al.; Effect of Troglitazone on Body Fat Distribution in Type 2 Diabetic Patients; Diabetes Care, June 1999; p. 908-912, Vo. 22, No. 6.	
		VIDAL-PUIG, A. et al.; Peroxisome Proliferator-activated Receptor Gene Expression in Human Tissues; J. Clin. Invest.; May 1997, p. 2416-2422, Vol. 99, No. 10.	
		TSAL, Y. et al.; Hypertension and abnormal fat distribution but not insulin resistance in mice; J. of Clinical Investigation; July 2004, p. 240-249, Vo. 114, No. 2.	
		Rawlings, A.; Cellulite and its treatment; J. of Cosmetic Science; 2006; p. 175-190, Vol. 28.	
		BIRNBAUM, L.; Addition of Conjugated Linoleic Acid to a Herbal Anticellulite Pill; Advances in Natural Therapy; Sep/Oct. 2001, p. 225-229, Vol. 18, No. 5.	
		BERTIN, C. et al.; A double-blind evaluation of the activity of an anti-cellulite product; J. Cosmet. Sci; Jul/Aug 2001, p. 199-210, Vol., 52, No. 4.	
		RAO, J. et al., A two-center, double-blinded, randomized trial testing the tolerability and efficacy; J. of Cosm. Derm., 2005, p. 93-102, Vol. 4.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call, 1-800-PTO-9199 (1-800-786-9199) and select option 2.